Enhancer–Gene Pair Validation: Technical Roadmap

Most regulatory projects start with a scan — H3K27ac, ATAC-seq, an enhancer atlas, a GWAS credible set — and land on a candidate element. The technical question that follows is narrow and specific: does this element regulate this gene? Answering it well depends on something usually decided implicitly and too late: the exact claim you intend to publish.

"Our data suggest an enhancer–gene link" and "we show that this 400-bp element drives GENE X expression in hepatocytes, and the risk allele reduces that activity by 30%" are different claims requiring different evidence. Deciding which claim you are making determines the guides you order, the cell lines you build, the replicates you run, and the statistics you need.

This article is the evidence roadmap for that decision. For the underlying biology of promoters, enhancers and 3D contacts — and for the wider menu of perturbation tools — see our pillar article on promoters, enhancers and 3D genome organization; here we assume the mechanism is familiar and focus entirely on what counts as proof.

Four claims are commonly conflated. Each has a different evidentiary bar:

Writing the claim down first is not administrative. It eliminates the most common waste in regulatory projects: producing activity-level evidence for a causality-level manuscript, then rebuilding everything under review.

Tier 0 — Correlation. Accessibility, histone marks, conservation, predicted contact. Useful for nomination only. No reviewer will accept a functional claim from Tier 0 alone, and in high-impact venues it is now routinely criticized when presented as more.

Tier 1 — Element necessity. Perturbation of the element with a matched readout. This is the first tier that supports "functional enhancer". It does not yet establish which gene is affected — the target-gene attribution is a separate inference and the most frequent weak point in review.

Tier 2 — Target-gene linkage. The perturbation is shown to change expression of a specific nominated gene, with a dose or magnitude consistent with the proposed mechanism, and with alternative targets excluded (neighbouring genes, the other allele, the same locus in a second cell background). Tier 2 is where a paper becomes mechanistic rather than descriptive.

Tier 3 — Allele-level causality. For variant work: an isogenic edit of the variant (not the whole element) reproduces a directionally consistent expression change, with allele-specific or reporter-based quantification. Rescue — reverting the edit — is the strongest available support in cell models and is increasingly requested.

Tier 4 — Architectural necessity. For claims that the effect works through a specific contact or boundary, the contact itself must be perturbed (boundary motif inversion/deletion, acute cohesin loss) and the expression consequence measured. Tier 4 is optional for most enhancer papers and mandatory for 3D-genome claims.

A practical rule: state your tier in the manuscript, not just your conclusion. Reviewers respond well to explicit calibration and poorly to inflated claims built on Tier 1 data.

1. Lock the cell background. The element must be active in the cells you will perturb, in the state you will perturb it. Ascertain this before ordering anything; many projects fail here and discover it after cloning.
2. Fix the readout. One primary readout per target gene, defined in advance (qPCR with defined primer efficiency, or RNA-seq with a stated analysis model). Decide whether you need isoform-level or allele-level resolution.
3. Perturb the element, not just the region. Design multiple independent perturbations (several guides, or two independent deletions with distinct breakpoints) so the effect is attributable to the element rather than to one construct.
4. Quantify before you interpret. Report effect size with confidence intervals; a 20% change with n=2 is not a finding. Pre-specify the biologically meaningful threshold — our separate piece on effect-size thresholds discusses how to set one defensibly.
5. Test target specificity. Measure the nearest genes, the gene on the other allele where relevant, and at least one unrelated control locus. This is what converts Tier 1 into Tier 2.
6. Add a second, orthogonal perturbation. A different modality (deletion plus interference, or interference plus activation) answers the "is this an artifact of one tool" objection before it is raised. The choice between modalities is covered in our comparison of deletion and CRISPRi for regulatory elements.
7. Convert to a scalable format if the project continues. An endogenous reporter line turns the validated pair into a screening or dose–response platform — see the guide to building reporter cell lines.
8. Pre-register the analysis, then write the figure plan. Figures should follow the tier structure: activity → necessity → target linkage → variant/rescue.

• • Guide coverage. Report how many independent perturbations targeted the element and where they landed. A single guide is a single data point, not a perturbation.
• • Replicate structure. Biological replicates across independent differentiations or passages; technical replicates do not substitute, and pseudo-replication of one clone is the single most common statistical flaw in regulatory papers.
• • Multiple testing. Tiling a 2-kb element with 40 guides and reporting the best-performing one inflates false positives. Either pre-specify the region and use a region-level test, or correct across guides.
• • Effect-size reporting. Absolute and relative change, with the assay's own variability as context. Percentage claims without a denominator are unverifiable.
• • Batch structure. Editing batches and assay batches should be balanced across conditions, not nested within them.

None of these are exotic. They are simply easier to design in than to add later.

A well-supported negative — "this element is dispensable for this gene in this cell type" — is publishable and useful, provided it is not a power failure. The requirements are the same as for a positive result: multiple perturbations, adequate replication, a demonstrated positive control in the same experiment, and an explicit statement of the smallest effect size the design could have detected. Our article on reporting negative results in regulatory element studies develops this into a reporting template.

A frequent reviewer objection is that a null result reflects the wrong cell type rather than element dispensability. Answering it requires either a second background or a positive control element known to be required in the same cells.

EDITGENE builds the perturbed and reporter cell systems behind these claims: element-targeted CRISPRi and deletion lines, isogenic variant pairs, endogenous reporter knock-ins, and CRISPRi/a-ready backgrounds — each delivered with genotypic, expression, and functional validation.

Describe your element, candidate target gene, and intended claim, and we will map it onto the evidence tiers above and propose a build strategy. Contact EDITGENE to request a project consultation or quote.

This roadmap describes evidentiary logic, not a universal protocol. Requirements differ by journal, field, and claim; effect sizes and the feasibility of each tier vary by locus, cell type, and assay sensitivity.

Tier assignments are a communication device, not a formal standard. Any engineered cell model should be validated to the level its intended application requires, including on-target sequencing, copy-number and zygosity assessment, expression measurement, functional assays, identity testing, and stability assessment.

• • Fulco CP, et al. Systematic mapping of functional enhancer–promoter connections with CRISPR interference. Science. 2016;354:769–773.
• • Gasperini M, et al. A genome-wide framework for mapping gene regulation via cellular genetic screens. Cell. 2019;176:377–390.
• • Nasser J, et al. Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021;593:238–243.
• • Kvon EZ, et al. Progressive loss of function in a limb enhancer during snake evolution. Cell. 2016;167:633–642.
• • Osterwalder M, et al. Enhancer redundancy provides phenotypic robustness in mammalian development. Nature. 2018;554:239–243.